估算癌症患者的治愈比例与其他原因死亡风险:EUROCARE-6关于头颈癌、结直肠癌和乳腺癌的数据
该研究采用新模型校正癌症患者死于其他原因的额外风险(RR),基于EUROCARE-6中65个欧洲癌症登记处1998–2002年诊断、随访至2014年12月31日的40–79岁头颈癌、结直肠癌和乳腺癌患者数据,估算净生存和治愈比例(CF)。年轻男性头颈癌患者死于其他原因的风险是同龄人的4倍,该风险随年龄降至1.6;新模型使CF绝对增加30%。
要点
- 年轻男性头颈癌患者死于其他原因的风险是同龄人的4倍,随年龄降至1.6,女性结果相似。
- 使用新模型替代传统模型后,头颈癌治愈比例绝对增加30%。
- 女性乳腺癌治愈比例在新模型下为73%–79%,RR为1.2–1.4。
核心结论
- 不考虑RR>1会低估不再死于所诊断癌症的患者比例。
- 癌症死亡风险估计对患者生活质量有重要影响。
研究设计与样本
- 采用新模型校正患者死于非所诊断癌症原因的额外风险(RR),同时估算净生存和治愈比例(CF)。
- 分析EUROCARE-6中65个欧洲癌症登记处提供的头颈癌、结直肠癌和乳腺癌患者数据,年龄40–79岁,1998–2002年诊断,随访至2014年12月31日。
主要发现
- 年轻男性头颈癌患者死于其他原因的风险是同龄人的4倍,该风险随年龄降至1.6,女性结果相似。
- 使用新模型替代传统模型后,头颈癌治愈比例绝对增加30%。
- 结直肠癌新模型治愈比例在老年患者中最大增加3%,男女RR范围为1–1.2。
- 女性乳腺癌新模型治愈比例为73%–79%,RR为1.2–1.4。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To estimate net survival and cancer cure fraction (CF), i.e. the proportion of patients no longer at risk of dying from cancer progression/relapse, a clear distinction needs to be made between mortality from cancer and from other causes. Conventionally, CF is estimated assuming no excess mortality compared to the general population. METHODS: A new modelling approach, that corrects for patients' extra risk of dying (RR) from causes other than the diagnosed cancer, was considered to estimate both indicators. We analysed EUROCARE-6 data on head and neck (H&N), colorectal, and breast cancer patients aged 40-79, diagnosed from 1998 to 2002 and followed-up to 31/12/2014, provided by 65 European cancer registries. FINDINGS: Young male H&N cancer patients have 4 times the risk of dying from other causes than their peers, this risk decreases with age to 1.6. Similar results were observed for female. We observed an absolute increase in CF of 30 % using the new model instead of the conventional one. For colorectal cancer, CF with the new model increased by a maximum of 3 % for older patients and the RR ranged from 1 to 1.2 for both sexes. CF of female breast cancer ranged from 73 % to 79 % using the new cure model, with RR between 1.2 and 1.4. INTERPRETATION: Not considering a RR> 1 leads to underestimate the proportion of patients not bound to die of their diagnosed cancer. Estimates of cancer mortality risk have an important impact on patients' quality of life.
引用
- Botta L, Capocaccia R, Bernasconi A, et al. Estimating cure and risk of death from other causes of cancer patients: EUROCARE-6 data on head & neck, colorectal, and breast cancers. Eur J Cancer. 2024. PMID: 39013266. doi:10.1016/j.ejca.2024.114187
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。